Oncologia
Diretriz ESTRO-ACROP para a radioterapia guiada por superfície.
14 Jun, 2022 | 12:49hESTRO-ACROP guideline on surface guided radiation therapy – Radiotherapy & Oncology
Comentário no Twitter
Now available! First European guideline on Surface Guided Radiation Therapy (SGRT): ESTRO-ACROP guideline on surface guided radiation therapy👉https://t.co/YC8Vk8g4h1 @OncologyAdvance @RadiotherapyOn1 #Radonc #Radiotherapy #Oncology
— ESTRO (@ESTRO_RT) June 2, 2022
#ASCO22 – Estudo randomizado | Fluorouracil, leucovorina, oxaliplatina e irinotecano com panitumumabe vs. fluorouracil, leucovorina e oxaliplatina com panitumumabe para pacientes com câncer colorretal metastático tipo RAS/BRAF agressivo.
14 Jun, 2022 | 12:47h#ASCO22 – Estudo randomizado | Monoterapia com rucaparibe como tratamento de manutenção para pacientes com câncer de ovário recém-diagnosticado.
14 Jun, 2022 | 12:46hRevisão | Urgências e emergências oncológicas.
13 Jun, 2022 | 15:05hOncologic emergencies and urgencies: A comprehensive review – CA: A Cancer Journal for Clinicians
Comentário no Twitter
🎯Just in time for #ASCO22 | Oncologic emergencies and urgencies: A comprehensive review https://t.co/HyZmI37tr5 @BEGouldRothberg @YaleCancer @KeithDelman
CC: @OncoAlert pic.twitter.com/57tqiLXijN— CA: A Cancer Journal for Clinicians (@CAonline) June 2, 2022
#ADA2022 – Estudo de coorte retrospectiva | Associação entre cirurgia bariátrica e risco de câncer e mortalidade em adultos com obesidade.
13 Jun, 2022 | 14:58hAssociation of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity – JAMA (gratuito por tempo limitado)
Editorial: Bariatric Surgery and Cancer Risk – JAMA (gratuito por tempo limitado)
Comunicado de imprensa: Weight loss with bariatric surgery cuts the risk of developing cancer and death from cancer – Cleveland Clinic
Comentários no Twitter
In this study, among adults with #obesity, #bariatricsurgery compared with no surgery was associated with a significantly lower incidence of obesity-associated #cancer and cancer-related mortality. https://t.co/x2gz3RUdra
— JAMA (@JAMA_current) June 3, 2022
Retrospective cohort presented at the @AmDiabetesAssn: incidence rate of 3.0 events vs 4.6 events per 1,000 person-years, resp, & a 32% reduced risk for developing obesity-related cancer following weight loss via surgery. @ClevelandClinic
https://t.co/6jLDmhgJbR @JAMA_current
— Karl Nadolsky (@DrKarlNadolsky) June 4, 2022
#ASCO2022 – Estudo randomizado | Análise do DNA circulante de tumor como orientação para terapia adjuvante no câncer de cólon estágio II.
13 Jun, 2022 | 14:56hCirculating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comunicado de imprensa: DNA shed from colon cancers into bloodstream successfully guides chemotherapy after surgery – Helps clarify the benefit of chemotherapy in stage II cancers – Johns Hopkins Medicine
Comentário: ctDNA Effectively Detects When Adjuvant Chemo Is Avoidable in Stage II Colon Cancers – Cancer Network
Comentário no Twitter
DYNAMIC: Among patients with stage II colon cancer, a ctDNA-guided management approach reduced the use of adjuvant chemotherapy without increasing the risk of recurrence. #ASCO22 https://t.co/xXjXyPXRC9 pic.twitter.com/gvHMnGWbyE
— NEJM (@NEJM) June 4, 2022
Diretrizes para o sarcoma de Kaposi.
13 Jun, 2022 | 14:47hS1 Guidelines for the Kaposi Sarcoma – Journal of the German Society of Dermatology
#ASCO22 – Estudo randomizado | Trastuzumabe deruxtecam no câncer de mama avançado previamente tratado com baixo HER2.
13 Jun, 2022 | 14:45hTrastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentário no Twitter
DESTINY-Breast04: In a phase 3 trial, trastuzumab deruxtecan resulted in longer progression-free and overall survival than the physician’s choice of chemo among patients with HER2-low breast cancer. #ASCO22 https://t.co/bgheQ1yolb pic.twitter.com/nfRMcIh9Ly
— NEJM (@NEJM) June 5, 2022
#ASCO22 – Estudo randomizado | Ibrutinibe com bendamustina e rituximabe no linfoma de células do manto.
13 Jun, 2022 | 14:43hIbrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comunicado de imprensa: Ibrutinib with chemoimmunotherapy improved progression-free survival for newly diagnosed mantle cell lymphoma patients – BTK inhibitor as front-line option for MCL – University of Texas M. D. Anderson Cancer Center
#ASCO22 – Estudo de braço único fase 2 | Adagrasibe em câncer de pulmão de não pequenas células abrigando uma mutação KRASG12C.
13 Jun, 2022 | 14:42hAdagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comunicado de imprensa: Targeted drug achieves 43% response rate in KRAS-mutated lung cancer – Dana-Farber Cancer Institute